Eudragit® S 100-Coated Lipid Nanoparticles: Advancing Oral RNA Delivery

Study Background and Research Question

RNA-based therapeutics have rapidly advanced over the past decade, highlighted by the success of siRNA treatments such as Onpattro and mRNA vaccines against infectious diseases. These breakthroughs have relied on lipid nanoparticle (LNP) formulations to stabilize and deliver nucleic acid payloads effectively to target cells according to the recent study by Haque et al. (2025). However, while injectable modalities (intravenous, intramuscular) have been the mainstay for clinical delivery, oral administration of RNA remains a major challenge. The gastrointestinal (GI) tract presents harsh conditions—including low pH, digestive enzymes, and ribonucleases—that rapidly degrade unprotected RNA, limiting therapeutic potential for oral gene delivery systems. The core research question addressed in this study was: Can LNPs, protected with a pH-responsive polymer coating, enable stable and effective oral delivery of RNA payloads?

Key Innovation from the Reference Study

Haque et al. introduce a novel strategy to overcome the GI tract’s degradative environment by coating LNPs with Eudragit® S 100 (Eu), a methacrylic acid-methyl methacrylate copolymer known for its pH-dependent solubility. This enteric polymer remains insoluble in acidic gastric conditions but dissolves at higher (intestinal) pH values, releasing its payload where absorption is feasible. While Eudragit® has been widely used to protect labile molecules, its specific application to RNA-LNP oral delivery is a significant technical advance. The study demonstrates that such coatings can shield nucleic acids, including mRNA, from gastric degradation and facilitate their release and transfection in cell models (Haque et al., 2025).

Methods and Experimental Design Insights

The researchers formulated LNPs using a well-characterized composition: DLin-MC3-DMA ionizable lipid, cholesterol, DMG-PEG, and DSPC at a 50:38.5:10:1.5 molar ratio. Eudragit® S 100 was applied as a 1% solution via nanoprecipitation in 0.25% acetic acid, producing Eu-coated LNPs (Eu-LNPs). Particle size and surface characteristics were assessed by dynamic light scattering (DLS), revealing uncoated LNPs of ~120 nm and Eu-LNPs of ~4.5 μm. Upon exposure to pH 8 (intestinal conditions), Eu-LNPs disintegrated to ~191 ± 22.9 nm, indicating polymer dissolution and nanoparticle release. Ribogreen fluorescence and agarose gel retardation assays quantified RNA encapsulation efficiency and protection against enzymatic degradation. For biological relevance, HEK-293 cell transfections were carried out using both treated and untreated LNP/Eu-LNP preparations, before and after exposure to simulated gastric fluid (SGF) and simulated intestinal fluid.

Protocol Parameters

• LNP formulation: DLin-MC3-DMA:cholesterol:DMG-PEG:DSPC (50:38.5:10:1.5 molar ratio).
• Eudragit® S 100 coating: 1% solution via nanoprecipitation in 0.25% acetic acid.
• Particle size characterization: Dynamic light scattering (DLS); uncoated LNPs ~120 nm, Eu-LNPs ~4.5 μm (pre-dissolution), ~191 nm (post-pH 8 exposure).
• Stability assays: Ribogreen fluorescence for nucleic acid quantification, agarose gel retardation for protection/stability.
• Simulated GI exposure: Simulated gastric fluid (pepsin-containing, low pH) and simulated intestinal fluid to mimic oral delivery route.
• Transfection assays: HEK-293 cells, comparing PB-treated and untreated Eu-LNPs, uncoated LNPs.

Core Findings and Why They Matter

The study provides clear evidence that Eudragit® S 100-coated LNPs are highly effective in protecting RNA cargo from acidic and enzymatic degradation during simulated gastric transit. After exposure to simulated gastric and intestinal fluids, Eu-LNPs maintained RNA integrity and transfection potential in cultured cells. Notably, Eu-LNPs treated with phosphate buffer (to mimic intestinal pH-mediated dissolution) demonstrated robust transfection in HEK-293 cells, outperforming non-PB-treated controls. This confirms the utility of a pH-responsive polymer barrier for staged release of LNPs in the small intestine, where absorption is optimal. These results highlight a practical path forward for oral gene delivery systems using bioluminescent reporter mRNA, such as Firefly Luciferase mRNA, for in vivo imaging and gene expression assays in preclinical and translational studies.

Comparison with Existing Internal Articles

Several internal resources focus on Firefly Luciferase mRNA as a bioluminescent reporter for gene expression and in vivo imaging (see Atomic Facts & Benchmarks, Stability and Mechanism, and Next-Gen Reporter Applications). These articles emphasize the molecular engineering of Firefly Luciferase mRNA (ARCA, 5-moUTP) for enhanced stability, immune evasion, and robust protein expression in cellular and animal models. While these resources address mRNA stability and translational performance, the reference study by Haque et al. uniquely extends the discussion to formulation and delivery challenges specific to oral administration. The internal article "Eudragit® S 100-Coated Lipid Nanoparticles for Oral RNA Delivery" aligns closely, confirming that Eudragit® coatings can protect nucleic acids in hostile GI environments and enable controlled intestinal release. Collectively, these resources underscore the importance of both nucleotide-level engineering (e.g., 5-methoxyuridine modification, ARCA capping) and advanced delivery systems (e.g., Eu-LNPs) for success in oral mRNA therapeutics.

Limitations and Transferability

Although the study provides compelling in vitro and ex vivo evidence, several limitations remain. First, the research primarily utilizes HEK-293 cell transfection as a proof-of-concept model; in vivo efficacy, tissue distribution, and immunogenicity after oral administration remain to be established. The observed size increase of Eu-LNPs prior to pH-triggered dissolution may also influence GI transit and uptake kinetics. Additionally, the scalability of the nanoprecipitation coating process for clinical-grade manufacturing is not addressed. Transferability to other RNA cargos—including chemically modified mRNAs like Firefly Luciferase mRNA (ARCA, 5-moUTP)—is promising given shared physicochemical challenges, but requires further validation in animal models and diverse tissue contexts.

Research Support Resources

To facilitate research on bioluminescent reporter mRNA delivery and oral gene therapy, scientists can incorporate Firefly Luciferase mRNA (ARCA, 5-moUTP) (SKU R1012) from APExBIO into their protocols. This reagent features ARCA capping and 5-methoxyuridine modification for enhanced stability and translational efficiency, making it well-suited as a model mRNA in gene expression and in vivo imaging assays. Its robust design aligns with the requirements for advanced LNP-based and polymer-coated delivery systems, as described in Haque et al. (2025). For further insight into optimized workflow strategies and technical benchmarks, researchers may consult the above-linked internal reviews.